Download presentation
Presentation is loading. Please wait.
1
New Lipid-Lowering Therapies
2
Challenges in the Post Statin Era
3
Identification of the Ideal Candidates
4
IMPROVE-IT No Signal of Adverse Consequence of Very Low LDL
5
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound (GLAGOV)
6
New Lipid-Lowering Therapies
7
Statin Intolerance
8
Role of PCSK9 Inhibitors in Statin-Intolerant Patients*
9
Percent LDL-C Reduction vs Myalgia Rates Evolocumab
10
New Lipid-Lowering Therapies
11
TESLA Part B: Percent Change in UC LDL-C From Baseline to Week 12
12
LDL Levels in FH From a Lethal Disorder to a Manageable Dyslipidemia
13
Homozygous FH
14
New Lipid-Lowering Therapies
15
OSLER Program
16
Evolocumab OSLER Trial Cumulative Incidence of Cardiovascular Events*
17
ODYSSEY Long-term CVD Risk and Statin Use
18
ODYSSEY LONG TERM: Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
19
OSLER AEs by Achieved LDL-C
20
ODYSSEY LONG-TERM Study AEs
21
ODYSSEY OUTCOMES: Summary of AEs by Achieved LDL-C No. of Patients (%)
22
Abbreviations
23
Abbreviations (cont)
24
Abbreviations (cont)
25
References
26
References (cont)
27
References (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.